Non-Alcoholic Fatty Liver Disease and its Link to Chronic Illnesses, Unraveling the Hidden Epidemic. скачать в хорошем качестве

Non-Alcoholic Fatty Liver Disease and its Link to Chronic Illnesses, Unraveling the Hidden Epidemic.

Professor Robert Lustig, a professor of Pediatric Endocrinology, is giving a presentation on non-alcoholic fatty liver disease (NAFLD) and its connection to chronic diseases like type 2 diabetes. NAFLD affects a significant portion of the population without their knowledge. Dr. Lustig emphasizes the importance of understanding the cause and pathogenesis of this disease, as it has become prevalent even in children who don't consume alcohol. He challenges the notion that obesity alone is the primary cause of metabolic diseases, presenting data showing that lean individuals also suffer from these conditions. He explains that the measurement of fat on the scale does not accurately determine a person's health status. Dr. Lustig highlights the significance of insulin resistance as a key factor in determining the development of diabetes and other chronic diseases. He discusses the different fat depots in the body, namely subcutaneous fat and visceral fat, and how their distribution and metabolic activity affect health outcomes. Dr. Lustig considers sugar (glucose-fructose) as a hazardous substance that can alter one metabolic pathway and help develop fatty liver. we encourage everyone to also watch other YouTube videos of Dr. Lustig on Emery Pharma channel:    • The Subcellular Processes That Belie All C...      • Professor Lustig’s Hateful - Grateful 8, f...      • Non-Alcoholic Fatty Liver Disease and its ...   About Emery Pharma: Emery Pharma is a full-service contract research laboratory, supporting the end-to-end development of small molecule drugs, biologics, biosimilars, gene therapy, botanicals, and more. Emery Pharma's premium services include analytical, bioanalytical solutions, microbiology & cell biology services, drug and impurity characterization, and general R&D and cGMP/GLP support. At Emery Pharma, our focus is to find innovative solutions for our Clients’ toughest challenges and tailoring those solutions to fit each Client’s unique needs. Our experienced scientific team will manage the process: from drug discovery, proof-of-concept, data management, data analysis, to gathering insights. The team excels at solving scientific challenges, and addressing any issues early in the process, so Clients don’t experience unnecessary setbacks. Emery Pharma’s experienced chemists and biologists deploy state-of-the-art technology. Instrumentation ranges from high-resolution mass spec (Orbitrap), Triple quad LC-MS/MS, GC-MS, Preparative HPLC, and 400 MHz multinuclear NMR. Contact us: [email protected] https://emerypharma.com/ kewords: Emery Pharma Speaker Series Professor Lustig Pediatric Endocrinology Sugar: The Bitter Truth metabolica Non-alcoholic fatty liver disease Silent killer Pathogenesis Type 2 diabetes Lean diabetes Normal weight Risk factor Metabolic disease Metabolically healthy obese Metabolically healthy Obesity pandemic Chronic disease BMI Growth hormone receptor mutation The Little Women of Loha Larone dwarfism Insulin resistance Lipodystrophy Adipose tissue Visceral fat Subcutaneous fat Metabolic Health Waist circumference Acute stress Norepinephrine Beta-3 adrenergic receptor Lipolysis Triglyceride